{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:52:08Z","timestamp":1790218328243,"version":"4.1.0"},"reference-count":18,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2015,7,3]]},"DOI":"10.1586\/14760584.2015.1043273","type":"journal-article","created":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T00:21:36Z","timestamp":1430958096000},"page":"909-911","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":27,"title":["Are we entering a new age for human vaccine adjuvants?"],"prefix":"10.1586","volume":"14","author":[{"given":"Derek T","family":"O\u2019Hagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,5,6]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-4615-1823-5_7","volume-title":"Vaccine design: The subunit and adjuvant approach","author":"Vogel FR","year":"1995"},{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/298347a0","volume":"298","author":"Valenzuela P","year":"1982","journal-title":"Nature"},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/08830189009061764","volume":"7","author":"Edelman R","year":"1990","journal-title":"Int Rev Immunol"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2013.811188"},{"key":"CIT0006","volume-title":"GSK announces EU regulatory submission for malaria vaccine candidate RTS,S","author":"GlaxoSmithKline","year":"2014"},{"key":"CIT0007","volume-title":"Novartis receives in approval in Canada for Fluad PediatricTM, the first vaccine designed to help better protect infants from seasonal flu","author":"Novartis","year":"2015"},{"key":"CIT0008","volume-title":"Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint","author":"GlaxoSmithKline","year":"2014"},{"key":"CIT0009","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","volume":"200","author":"Kester KE","year":"2009","journal-title":"J Infect Dis"},{"key":"CIT0010","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","volume":"367","author":"RTS\/S-Clinical-Trials-Partnership","year":"2012","journal-title":"N Engl J Med"},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1010331","volume":"365","author":"Vesikari T","year":"2011","journal-title":"N Engl J Med"},{"key":"CIT0012","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1097\/INF.0000000000000462","volume":"33","author":"Knuf M","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"CIT0013","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/intimm\/dxp017","volume":"21","author":"Kawai T","year":"2009","journal-title":"Int Immunol"},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"263ra160","DOI":"10.1126\/scitranslmed.3009980","volume":"6","author":"Wu TY","year":"2014","journal-title":"Sci Trans Med"},{"key":"CIT0016","doi-asserted-by":"crossref","first-page":"e33536","DOI":"10.1371\/journal.pone.0033536","volume":"7","author":"Nohynek H","year":"2012","journal-title":"PLoS ONE"},{"key":"CIT0017","doi-asserted-by":"crossref","first-page":"e114361","DOI":"10.1371\/journal.pone.0114361","volume":"9","author":"Vaarala O","year":"2014","journal-title":"PLoS One"},{"key":"CIT0018","author":"Food and Drug Administration","year":"2015","journal-title":"A (H7N9) VLP antigen dose-ranging study with matrix-M1\u2122 Adjuvant: NCT02078674"},{"key":"CIT0019","author":"Food and Drug Administration","year":"2015","journal-title":"Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine: NCT0199156"},{"key":"CIT0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.smim.2013.05.007","volume":"25","author":"Brito LA","year":"2013","journal-title":"Sem Immunol"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14760584.2015.1043273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T07:05:59Z","timestamp":1498201559000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14760584.2015.1043273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,6]]},"references-count":18,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,5,6]]},"published-print":{"date-parts":[[2015,7,3]]}},"alternative-id":["10.1586\/14760584.2015.1043273"],"URL":"https:\/\/doi.org\/10.1586\/14760584.2015.1043273","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]}}